Contact Us

Crestor
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date you started taking this drug:

Date you stopped taking this drug:

Has Rhabdomyolysis been diagnosed?

If yes, when was Rhabdomyolysis diagnosed?

Have You Suffered Any Of These Side Effects:



Please further describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


ASTRAZENECA ISSUES WARNING LETTER TO BRITISH PHYSICIANS REGARDING OFF-LABEL CRESTOR USE

May 18, 2004 | www.pharmexec.com

AstraZeneca Plc issued a warning letter to British physicians regarding off-label prescribing of its statin Crestor (rosuvastatin), Reuters reported.

After discovering four cases of rhabdomyolysis a muscle toxicity condition that can lead to kidney damage among high-dose Crestor users, the company cautioned physicians to adhere to indications on the label and not begin patients on high doses of the drug.

AstraZeneca advised that patients be administered 10 mg doses of Crestor initially and be increased to 20 mg or 40 mg doses only as required.

The rate of adverse events from Crestor use was similar to the side effect profile observed in other competing statins. The four cases of rhabdomyolysis occurred after patients were initiated on a high Crestor dose, according to AstraZeneca spokeswoman Kirsty Walker.


Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo